ARCH Venture Partners XII, LLC bought $3.1M of City Therapeutics (CTY)

Executed Oct 19, disclosed Oct 19, the same day.

Value, as filed

$3.1M

170,000 sh × $18.00

Executed

Oct 19

the trade date, as filed

Disclosed

Oct 19

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

AL ARCH Venture Partners XII, LLC 10% owner profile →

ARCH Venture Partners XII, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in City Therapeutics, Inc. (CTY). Across 1 priced purchase filing, the average 21-session return was -10.2% from execution and -10.2% from disclosure (delay-adjusted; derived). The largest single filing was $19.8M of SPTX (1,100,000 sh × $18.00, as filed), executed May 4.

The name

CTY

City Therapeutics, Inc. CTY · Healthcare · 2 filings in 24 months ticker →

Healthcare · City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineerin…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→